Team
BRIM Biotechnology brings together experts across science, engineering, and technology disciplines to deliver a more efficient, less costly, drug development process. Our talented team has forged decades worth of strong global connections and experience. We operate based on a virtual biotechnology model, integrating our expert R&D operation team in Taiwan with our skilled overseas scientific team. We have years of experience working in technological and pharmaceutical development, regulatory affairs, and marketing and IP, with expertise across the field of innovative drug development, including pre-clinical toxicology, clinical pharmacology and management. We harness the power of our team’s expertise in translational science to deliver a difference for patients.
<!DOCTYPE html>
<html>
<head>
<title>BRIM</title>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=no">
<style>
body {
font-family: Roboto, Helvetica, Arial, sans-serif;
}
.team-flower * {
box-sizing: border-box;
}
.team-flower {
position:relative;
display: block;
max-width:100%;
margin:0 auto;
box-sizing: content-box;
}
.team-flower__bg {
display:none;
}
.team-flower__title {
color:#007F85;
font-size:40px;
font-weight:600;
line-height:57px;
margin-bottom:1em;
}
.modal .team-flower__name,
.modal .team-flower__role {
text-align:center;
font-weight:600;
}
.modal .team-flower__name {
color:#007F85;
font-size:28px;
}
.modal .team-flower__role {
color:#4F4F4F;
font-size:18px;
margin-top:6px;
}
.modal .team-flower__bio {
text-align: center;
margin-top:15px;
}
.modal .team-flower__photo {
border-radius:100px;
width:200px;
max-width:100%;
border:0;
background:#007F85;
padding:2px;
margin: 0 auto 20px;
display: block;
}
@media (max-width:991px) {
.team-flower__title br {
display:none;
}
.team-flower__petal {
margin-bottom:20px;
}
.team-flower__department {
background: rgb(233,189,9);
background: -moz-linear-gradient(90deg, rgba(233,189,9,1) 0%, rgba(214,138,7,1) 100%);
background: -webkit-linear-gradient(90deg, rgba(233,189,9,1) 0%, rgba(214,138,7,1) 100%);
background: linear-gradient(90deg, rgba(233,189,9,1) 0%, rgba(214,138,7,1) 100%);
filter: progid:DXImageTransform.Microsoft.gradient(startColorstr="#e9bd09",endColorstr="#d68a07",GradientType=1);
color:#fff !important;
font-size:20px;
padding:12px 40px 12px 16px;
font-weight:600;
border-radius:10px;
position: relative;
display: block;
text-decoration: none;
}
.team-flower__department::before,
.team-flower__department::after {
content:"";
display:block;
width:2px;
height:12px;
background:#fff;
position:absolute;
right:16px;
top:19px;
border-radius:1px;
}
.team-flower__department::before {
transform:rotate(-45deg);
right: 24px;
}
.team-flower__department::after {
transform:rotate(45deg);
}
.team-flower__department.is-active::before {
right: 16px;
}
.team-flower__department.is-active::after {
right: 24px;
}
.team-flower__members {
padding-top:15px;
display:none;
}
.team-flower__members.is-open {
display:block;
}
.team-flower__member {
background-color:#ffffff;
border-radius:10px;
box-shadow: 0 3px 6px rgba(0, 0, 0, 0.16);
margin-bottom: 5px;
}
.team-flower__link .team-flower__photo {
max-width:100%;
width:115px;
border-radius:10px;
float: left;
margin-right: 20px;
}
.team-flower__link {
display:block;
padding: 15px 30px 15px 15px;
text-decoration: none;
color:#8E8E8E;
font-weight:600;
font-size:20px;
height: 145px;
display: flex;
flex-direction: column;
flex-wrap: wrap;
justify-content: center;
align-items: flex-start;
position: relative;
}
.team-flower__link::before,
.team-flower__link::after {
content:"";
display:block;
width:2px;
height:12px;
background:#007F85;
position:absolute;
right:16px;
top: calc(50% - 10px);
border-radius:1px;
}
.team-flower__link::before {
transform:rotate(-45deg);
top: calc(50% - 8px);
}
.team-flower__link::after {
transform:rotate(-135deg);
top: 50%;
}
.team-flower__popup {
display:none;
}
.team-flower__link .team-flower__name,
.team-flower__link .team-flower__role {
line-height:1em;
width: calc(100% - 135px);
max-width: calc(100% - 135px);
}
.team-flower__link .team-flower__name + .team-flower__role {
margin-top: 18px;
}
}
@media (max-width:349px) {
.team-flower__photo {
margin-right:10px;
}
.team-flower__link .team-flower__name,
.team-flower__link .team-flower__role {
width: calc(100% - 125px);
max-width: calc(100% - 125px);
}
}
@media (min-width:992px) {
.team-flower {
width:700px;
padding:40px;
margin: 50px auto;
}
.team-flower__bg {
display:block;
}
.team-flower__title {
color:#fff;
font-size:20px;
line-height:28px;
text-align: center;
width:190px;
padding:15px 30px;
margin:0 auto;
position:absolute;
top:50%;
left: 0;
right: 0;
transform:translateY(-50%);
margin-top: 10px;
}
/* all petals */
.team-flower__petal {
position:absolute;
border-radius: 90px;
top:50%;
left: 50%;
right: 45px;
transform-origin: center left;
}
/* (in clockwise from top )
first petal */
.team-flower__petal--1 {
right: 45px;
transform: translateY(-50%) rotate(-90deg);
}
.team-flower__petal--1 .team-flower__department {
background: linear-gradient(#F59B00, #ecb407);
transform: rotate(90deg);
}
/* second petal */
.team-flower__petal--2 {
transform: translateY(-50%) rotate(-36.5deg);
right:41px;
}
.team-flower__petal--2 .team-flower__member {
transform: rotate(-53.5deg);
}
.team-flower__petal--2 .team-flower__department {
background: linear-gradient(50deg, #e9bb08, #F59B00);
transform: rotate(36.5deg);
}
/* third petal */
.team-flower__petal--3 {
transform: translateY(-50%) rotate(15.25deg);
right:30px;
}
.team-flower__petal--3 .team-flower__member {
transform: rotate(-105.25deg);
}
.team-flower__petal--3 .team-flower__department {
background: linear-gradient(105deg, #e9bb08, #F59B00);
transform: rotate(-15.25deg);
}
/* fourth petal */
.team-flower__petal--4 {
transform: translateY(-50%) rotate(65.25deg);
right: 22px;
}
.team-flower__petal--4 .team-flower__member {
transform: rotate(-155.25deg);
}
.team-flower__petal--4 .team-flower__department {
background: linear-gradient(155deg, #e9bb08, #F59B00);
transform: rotate(-65.25deg);
}
/* fifth petal */
.team-flower__petal--5 {
transform: translateY(-50%) rotate(114.5deg);
right: 22px;
}
.team-flower__petal--5 .team-flower__member {
transform: rotate(-204.5deg);
}
.team-flower__petal--5 .team-flower__department {
background: linear-gradient(-155deg, #e9bb08, #F59B00);
transform: rotate(-114.5deg);
}
/* sixth petal */
.team-flower__petal--6 {
transform: translateY(-50%) rotate(164.25deg);
right:30px;
}
.team-flower__petal--6 .team-flower__member {
transform: rotate(-254.25deg);
}
.team-flower__petal--6 .team-flower__department {
background: linear-gradient(235deg, #e9bb08, #F59B00);
transform: rotate(-164.25deg);
}
/* seventh petal */
.team-flower__petal--7 {
transform: translateY(-50%) rotate(216deg);
right:41px;
}
.team-flower__petal--7 .team-flower__member {
transform: rotate(-306deg);
}
.team-flower__petal--7 .team-flower__department {
background: linear-gradient(315deg, #ebb707, #f59b00);
transform: rotate(-216deg);
}
.team-flower__department {
text-decoration:none;
width: 176px;
height: 176px;
text-align: center;
font-weight:600;
color:#fff !important;
margin-right: 0;
margin-left: auto;
padding: 30px;
display: flex;
flex-direction: column;
justify-content: center;
border-radius:100px;
font-size: 16px;
z-index:2;
position: relative;
line-height:1.5em;
overflow-wrap:normal;
}
.team-flower__members {
transition:height 0.5s, width 0.5s;
position: absolute;
top: 50%;
left: 270px;
width:160px;
height:80px;
border-radius:100%;
transform-origin: center;
transform: translate(-50%, -50%) rotate(90deg);
cursor:pointer;
}
.team-flower__members:hover,
.team-flower__department:hover + .team-flower__members,
.team-flower__department:focus + .team-flower__members,
.team-flower__department:active + .team-flower__members {
width:420px;
height:330px;
}
.team-flower__petal--7 .team-flower__members,
.team-flower__petal--2 .team-flower__members {
left:275px;
}
.team-flower__petal--3 .team-flower__members,
.team-flower__petal--6 .team-flower__members {
left:280px;
}
.team-flower__petal--4 .team-flower__members,
.team-flower__petal--5 .team-flower__members {
left:288px;
}
.team-flower__member {
z-index:1;
position:absolute;
top: 25%;
left: 40px;
}
.team-flower__member:first-child:last-child {
top:0;
left: calc(50% - 40px);
}
.team-flower__petal[data-members="2"] .team-flower__member:first-child,
.team-flower__member + .team-flower__member{
top: 0;
left: 27.5%;
}
.team-flower__petal[data-members="2"] .team-flower__member:last-child,
.team-flower__member + .team-flower__member + .team-flower__member {
top: 0;
right: 27.5%;
left: auto;
}
.team-flower__member + .team-flower__member + .team-flower__member + .team-flower__member {
top: 25%;
right: 40px;
left: auto;
}
.team-flower__link {
display: block;
width:79px;
height:79px;
border-radius:100%;
overflow: hidden;
box-shadow: 0 3px 6px rgba(0, 0, 0, 0.16);
}
.team-flower__link .team-flower__photo {
width:100%;
height:100%;
object-fit:cover;
border-radius:100%;
border:0;
background:#007F85;
padding:2px;
transition: background 0.25s;
}
.team-flower__link:hover .team-flower__photo,
.team-flower__link:active .team-flower__photo,
.team-flower__link:focus .team-flower__photo {
background:#F59B00;
}
.team-flower__link .team-flower__name,
.team-flower__link .team-flower__role {
display: none;
}
.team-flower__popup {
display:none;
}
}
/* MODAL */
body.brimf-modal-open {
pointer-events: none;
overflow:hidden;
}
body.brimf-modal-open #brimfl-modal {
display:block !important;
display:flex !important;
pointer-events: all;
}
.modal {
display:none !important;
position:fixed;
top:0;
bottom:0;
left:0;
right:0;
margin: 0;
background: rgba(0, 0, 0, 0.71);
backdrop-filter: blur(10px);
z-index:9999999;
display:flex;
flex-direction: column;
justify-content: center;
}
.modal__wrap {
position:relative;
padding:20px;
width:540px;
max-width: calc(100% - 40px);
margin:0 auto;
overflow-y: auto;
overflow-x: hidden;
}
@media (min-width:992px) {
.modal__wrap {
padding:40px;
}
}
@media (min-width:1200px) {
.modal__wrap {
padding:70px;
}
}
.modal__close {
display:block;
cursor:pointer;
width:44px;
height:44px;
position: absolute;
opacity:0.1;
margin: 0 !important;
transition: opacity 0.25s;
right: 20px;
top: 20px;
}
.modal__close::before,
.modal__close::after {
content:"";
display: block;
width:2px;
height:31px;
border-radius:1px;
background:#000000;
position:absolute;
top: 7px;
left: 21px;
}
.modal__close::before {
transform:rotate(-45deg);
}
.modal__close::after {
transform:rotate(45deg);
}
.modal__close:hover,
.modal__close:focus,
.modal__close:active {
opacity:0.2;
}
@media (min-width:992px) {
.modal__close {
right: 40px;
top: 40px;
}
}
@media (min-width:1200px) {
.modal__close {
right: 70px;
top: 70px;
}
}
@media (max-width:599px) {
.modal__close {
opacity:0.5;
}
.modal__close:hover,
.modal__close:focus,
.modal__close:active {
opacity:0.75;
}
}
.modal__content {
background:#fff;
border-radius:10px;
overflow:hidden;
min-height: 80px;
padding:22px;
margin: 0;
}
@media (min-width:992px) {
.modal__content {
padding:44px;
}
}
</style>
<script type="text/javascript">// Ready.
window.addEventListener('DOMContentLoaded', function () {
if (document.querySelectorAll('.team-flower__department')) {
const departments = document.querySelectorAll('.team-flower__department');
departments.forEach(function(department) {
department.addEventListener('click', departmentToggle);
});
}
function departmentToggle(e) {
e.preventDefault();
const href = this.getAttribute('href');
const targetMembers = document.querySelector(href);
if (targetMembers.className == 'team-flower__members is-open') {
targetMembers.className = 'team-flower__members';
this.className = 'team-flower__department';
} else {
targetMembers.className = 'team-flower__members is-open';
this.className = 'team-flower__department is-active';
}
}
// If modal needed
var modalTargets = document.querySelectorAll('a.team-flower__link');
var i = 0;
// If targets
if (modalTargets.length) {
// Set up modal
var modalEl = document.createElement('div');
modalEl.id = 'brimfl-modal';
modalEl.className = 'modal';
modalEl.innerHTML = '<div class="modal__wrap"><div class="modal__close"></div><div class="modal__content" id="modal-content"></div></div>';
document.querySelector('body').append(modalEl);
// Give all targets id
modalTargets.forEach(function(target) {
i++;
target.setAttribute('data-modal-id', i);
// On modal target click
target.addEventListener('click', targetClick);
});
function targetClick(e) {
e.preventDefault();
// Open modal
var currentBodyClasses = document.querySelector('body').className;
document.querySelector('body').className = currentBodyClasses + ' brimf-modal-open';
// Load modal with content from target
if (e.target.getAttribute('data-modal-id')) {
loadModal(e.target.getAttribute('data-modal-id'));
} else {
loadModal(e.target.parentElement.getAttribute('data-modal-id'));
}
}
var modalTotal = i;
// Close modal on outside click
var modal = document.getElementById('brimfl-modal');
modal.addEventListener('click', modalClick);
function modalClick(e) {
e.preventDefault();
if (e.target.className == 'modal__wrap' || e.target.className == 'modal') {
var currentBodyClasses = document.querySelector('body').className;
document.querySelector('body').className = currentBodyClasses.replace(' brimf-modal-open', '');
}
}
// Close modal on close button click
var modalClose = document.querySelector('#brimfl-modal .modal__close');
modalClose.addEventListener('click', modalCloseClick);
function modalCloseClick(e) {
e.preventDefault();
var currentBodyClasses = document.querySelector('body').className;
document.querySelector('body').className = currentBodyClasses.replace(' brimf-modal-open', '');
}
// Load modal function
function loadModal(id) {
// Remove old modal content
var modalContent = document.getElementById('modal-content');
modalContent.innerHTML = '';
var target = document.querySelector('a[data-modal-id="' + id + '"]').getAttribute('href');
// Get content for modal
var modal_data = document.querySelector(target).innerHTML;
// Take data and place into modal content area
modalContent.innerHTML = modal_data;
}
}
});</script>
</head>
<body class="just some example-classes">
<div class="page" style="max-width:100%;margin:0 auto;">
<div class="team-flower">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/flower.svg" alt="Flower" class="team-flower__bg">
<div class="team-flower__title">Translational Science Expertise</div>
<div class="team-flower__petal team-flower__petal--1" data-members="1">
<a class="team-flower__department" href="#flower-rdops">BRIM R&D Operational Team</a>
<div class="team-flower__members" id="flower-rdops">
<div class="team-flower__member">
<a href="#member-1" class="team-flower__link">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/team-shot-square.jpg" class="team-flower__photo" alt="BRIM R&D Operational Team">
<div class="team-flower__name">BRIM R&D</div>
<div class="team-flower__role">Operational Team</div>
</a>
<div class="team-flower__popup" id="member-1">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/team-shot-square.jpg" class="team-flower__photo" alt="BRIM R&D Operational Team">
<div class="team-flower__name">BRIM R&D</div>
<div class="team-flower__role">Operational Team</div>
</div>
</div>
</div>
</div>
<div class="team-flower__petal team-flower__petal--2" data-members="2">
<a class="team-flower__department" href="#flower-preclinical">Pre-clinical & Toxicology</a>
<div class="team-flower__members" id="flower-preclinical">
<div class="team-flower__member">
<a href="#member-5" class="team-flower__link">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/frank-lee.jpg" class="team-flower__photo" alt="Dr. Frank Lee">
<div class="team-flower__name">Dr. Frank Lee</div>
<div class="team-flower__role">Chief Strategy Officer & BRIM Cayman Chairman</div>
</a>
<div class="team-flower__popup" id="member-5">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/frank-lee.jpg" class="team-flower__photo" alt="Dr. Frank Lee">
<div class="team-flower__name">Dr. Frank Lee</div>
<div class="team-flower__role">Chief Strategy Officer & BRIM Cayman Chairman</div>
</div>
</div>
<div class="team-flower__member">
<a href="#member-6" class="team-flower__link">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/carl-alden.jpg" class="team-flower__photo" alt="Dr. Carl Alden">
<div class="team-flower__name">Dr. Carl Alden</div>
<div class="team-flower__role">Senior Fellow</div>
</a>
<div class="team-flower__popup" id="member-6">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/carl-alden.jpg" class="team-flower__photo" alt="Dr. Carl Alden">
<div class="team-flower__name">Dr. Carl Alden</div>
<div class="team-flower__role">Senior Fellow</div>
<div class="team-flower__bio">Previously Vice President at Millennium</div>
<div class="team-flower__bio">Held various roles at Searle, Monsanto, Pharmacia & P&G</div>
<div class="team-flower__bio">Served as Editor of Veterinary Pathology and Toxicology Pathology and President at Society of Toxicology Pathologist</div>
</div>
</div>
</div>
</div>
<div class="team-flower__petal team-flower__petal--3" data-members="2">
<a class="team-flower__department" href="#flower-clinical">Clinical Pharmacology & Clinical Management</a>
<div class="team-flower__members" id="flower-clinical">
<div class="team-flower__member">
<a href="#member-9" class="team-flower__link">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/haishan-jang.jpg" class="team-flower__photo" alt="Dr. Haishan Jang">
<div class="team-flower__name">Dr. Haishan Jang</div>
<div class="team-flower__role">Chairwoman & Chief Executive Officer</div>
</a>
<div class="team-flower__popup" id="member-9">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/haishan-jang.jpg" class="team-flower__photo" alt="Dr. Haishan Jang">
<div class="team-flower__name">Dr. Haishan Jang</div>
<div class="team-flower__role">Chairwoman & Chief Executive Officer</div>
</div>
</div>
<div class="team-flower__member">
<a href="#member-10" class="team-flower__link">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/conrad-tou.jpg" class="team-flower__photo" alt="Dr. Conrad Tou">
<div class="team-flower__name">Dr. Conrad Tou</div>
<div class="team-flower__role">Senior Fellow</div>
</a>
<div class="team-flower__popup" id="member-10">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/conrad-tou.jpg" class="team-flower__photo" alt="Dr. Conrad Tou">
<div class="team-flower__name">Dr. Conrad Tou</div>
<div class="team-flower__role">Senior Fellow</div>
<div class="team-flower__bio">30+ years of experience in biotech and large pharmaormer director at Hollis-Eden pharma</div>
<div class="team-flower__bio">Held several positions at Sanofi-Winthrop and AstraZeneca, with expertise in statistics and data management</div>
</div>
</div>
</div>
</div>
<div class="team-flower__petal team-flower__petal--4" data-members="1">
<a class="team-flower__department" href="#flower-cmc">CMC & Pharmaceutical Development</a>
<div class="team-flower__members" id="flower-cmc">
<div class="team-flower__member">
<a href="#member-13" class="team-flower__link">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/wayne-liaw.jpg" class="team-flower__photo" alt="Dr. Wayne Liaw">
<div class="team-flower__name">Dr. Wayne Liaw</div>
<div class="team-flower__role">Senior Fellow</div>
</a>
<div class="team-flower__popup" id="member-13">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/wayne-liaw.jpg" class="team-flower__photo" alt="Dr. Wayne Liaw">
<div class="team-flower__name">Dr. Wayne Liaw</div>
<div class="team-flower__role">Senior Fellow</div>
<div class="team-flower__bio">Previously held Senior Director positions at Otonomy and Optimer</div>
<div class="team-flower__bio">Former director at Hollis-Eden pharma</div>
</div>
</div>
</div>
</div>
<div class="team-flower__petal team-flower__petal--5" data-members="1">
<a class="team-flower__department" href="#flower-regulation">Regulation</a>
<div class="team-flower__members" id="flower-regulation">
<div class="team-flower__member">
<a href="#member-19" class="team-flower__link">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/su-lin.jpg" class="team-flower__photo" alt="Su Lin">
<div class="team-flower__name">Su Lin</div>
<div class="team-flower__role">VP of Operation</div>
</a>
<div class="team-flower__popup" id="member-19">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/su-lin.jpg" class="team-flower__photo" alt="Su Lin">
<div class="team-flower__name">Su Lin</div>
<div class="team-flower__role">VP of Operation</div>
</div>
</div>
</div>
</div>
<div class="team-flower__petal team-flower__petal--6" data-members="1">
<a class="team-flower__department" href="#flower-marketing">Marketing and IP</a>
<div class="team-flower__members" id="flower-marketing">
<div class="team-flower__member">
<a href="#member-23" class="team-flower__link">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/chyau-liang.jpg" class="team-flower__photo" alt="Dr. Chyau Liang">
<div class="team-flower__name">Dr. Chyau Liang</div>
<div class="team-flower__role">Senior Fellow</div>
</a>
<div class="team-flower__popup" id="member-23">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/chyau-liang.jpg" class="team-flower__photo" alt="Dr. Chyau Liang">
<div class="team-flower__name">Dr. Chyau Liang</div>
<div class="team-flower__role">Senior Fellow</div>
<div class="team-flower__bio">Previously Partner at Osha Liang LLP</div>
<div class="team-flower__bio">Former Professor at the University of Texas-Houston School of Medicine</div>
</div>
</div>
</div>
</div>
<div class="team-flower__petal team-flower__petal--7" data-members="4">
<a class="team-flower__department" href="#flower-sabs">SABs & KOLs</a>
<div class="team-flower__members" id="flower-sabs">
<div class="team-flower__member">
<a href="#member-27" class="team-flower__link">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/pan-chyr-yang.jpg" class="team-flower__photo" alt="Dr. Pan-Chyr Yang">
<div class="team-flower__name">Dr. Pan-Chyr Yang</div>
<div class="team-flower__role">Scientific Board Member</div>
</a>
<div class="team-flower__popup" id="member-27">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/pan-chyr-yang.jpg" class="team-flower__photo" alt="Dr. Pan-Chyr Yang">
<div class="team-flower__name">Dr. Pan-Chyr Yang</div>
<div class="team-flower__role">Scientific Board Member</div>
<div class="team-flower__bio">Academician at Academia Sinica and Professor at National Taiwan University</div>
<div class="team-flower__bio">Previously President of National Taiwan University</div>
<div class="team-flower__bio">Editor-in-Chief of MicroRNA and Lung Cancer: Targets and Therapy</div>
</div>
</div>
<div class="team-flower__member">
<a href="#member-28" class="team-flower__link">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/robert-ruffolo.jpg" class="team-flower__photo" alt="Dr. Robert Ruffolo">
<div class="team-flower__name">Dr. Robert Ruffolo</div>
<div class="team-flower__role">Scientific Board Member</div>
</a>
<div class="team-flower__popup" id="member-28">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/robert-ruffolo.jpg" class="team-flower__photo" alt="Dr. Robert Ruffolo">
<div class="team-flower__name">Dr. Robert Ruffolo</div>
<div class="team-flower__role">Scientific Board Member</div>
<div class="team-flower__bio">Previously President of R&D and Corporate Senior Vice President of Wyeth Pharmaceuticals</div>
<div class="team-flower__bio">Senior Vice President and Director of Research at SmithKline Beecham Pharmaceuticals</div>
<div class="team-flower__bio">Chairman of the Cardiovascular Research Committee at Eli Lilly & Company</div>
</div>
</div>
<div class="team-flower__member">
<a href="#member-29" class="team-flower__link">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/wenchyi-shyu.jpg" class="team-flower__photo" alt="Dr. Wen Chyi Shyu">
<div class="team-flower__name">Dr. Wen Chyi Shyu</div>
<div class="team-flower__role">Scientific Board Member</div>
</a>
<div class="team-flower__popup" id="member-29">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/wenchyi-shyu.jpg" class="team-flower__photo" alt="Dr. Wen Chyi Shyu">
<div class="team-flower__name">Dr. Wen Chyi Shyu</div>
<div class="team-flower__role">Scientific Board Member</div>
<div class="team-flower__bio">Vice President of Global Drug Metabolism and Pharmacokinetics at Takeda</div>
<div class="team-flower__bio">30+ years of experience in drug metabolism and pharmacokinetics</div>
</div>
</div>
<div class="team-flower__member">
<a href="#member-30" class="team-flower__link">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/eliot-lazar-1.jpg" class="team-flower__photo" alt="Dr. Eliot Lazar">
<div class="team-flower__name">Dr. Eliot Lazar</div>
<div class="team-flower__role">Scientific Board Member</div>
</a>
<div class="team-flower__popup" id="member-30">
<img src="https://www.brimbiotech.com/wp-content/uploads/2022/05/eliot-lazar-1.jpg" class="team-flower__photo" alt="Dr. Eliot Lazar">
<div class="team-flower__name">Dr. Eliot Lazar</div>
<div class="team-flower__role">Scientific Board Member</div>
<div class="team-flower__bio">CEO at elCON Medical Consulting</div>
<div class="team-flower__bio">Previously held Assistant Professor positions at the State University of NY and the University of Rochester</div>
</div>
</div>
</div>
</div>
</div>
</div>
</body>
</html>
Directors
James Cheng, JD
Mr James Cheng is a partner with Tsar & Tsai Law Firm and is both a litigator and a transaction attorney. His areas of specialty include corporate law, insurance, M&A, capital markets, cross-border transactions, BOT projects, and government procurement.
On the litigation side, James has assisted numerous high-tech companies on intellectual property disputes, directors of various companies on allegations of breach of trust and breach of fiduciary duty, contractors and construction consulting firms on construction defect cases, and companies having disputes relating to government projects.
On the transaction side, James is involved in numerous high-profile cross-border M&As by assisting the client in deal structure, contract negotiation, syndication loan documentation, and post-closing restructure.
As an insurance law expert, James also represents multiple insurance businesses in Taiwan on insurance business regulatory compliance matters and claim disputes.
James Cheng, JD
Mr James Cheng is a partner with Tsar & Tsai Law Firm and is both a litigator and a transaction attorney. His areas of specialty include corporate law, insurance, M&A, capital markets, cross-border transactions, BOT projects, and government procurement.
On the litigation side, James has assisted numerous high-tech companies on intellectual property disputes, directors of various companies on allegations of breach of trust and breach of fiduciary duty, contractors and construction consulting firms on construction defect cases, and companies having disputes relating to government projects.
On the transaction side, James is involved in numerous high-profile cross-border M&As by assisting the client in deal structure, contract negotiation, syndication loan documentation, and post-closing restructure.
As an insurance law expert, James also represents multiple insurance businesses in Taiwan on insurance business regulatory compliance matters and claim disputes.
Howard Kuo, MBA
Mr Howard Kuo currently serves on the board of directors in many public and private companies in Taiwan. After retiring from his role as Deputy Chairman of PwC Taiwan and as a lead accountant for Family Business Inheritance and Personal Assets and Tax Management, he continued to teach in the universities and provide guidance to startups. He has over 35 years of experience in accounting and extensive expertise in tax affairs and corporate cross-border investment structure and planning.
Howard holds an MBA from the Executive MBA Program of National Taiwan University.
Howard Kuo, MBA
Mr Howard Kuo currently serves on the board of directors in many public and private companies in Taiwan. After retiring from his role as Deputy Chairman of PwC Taiwan and as a lead accountant for Family Business Inheritance and Personal Assets and Tax Management, he continued to teach in the universities and provide guidance to startups. He has over 35 years of experience in accounting and extensive expertise in tax affairs and corporate cross-border investment structure and planning.
Howard holds an MBA from the Executive MBA Program of National Taiwan University.
Affinity Capital
Affinity Capital′s Great Health Fund No. 1 focuses on investing in Taiwan’s life science and health industries. The members of the management team are all senior experts with extensive experience in life sciences, capital markets, investment, mergers and acquisitions, and post-investment management, as well as profound capabilities in business operations.
![Photo of Affinity Capital]()
Affinity Capital
Affinity Capital′s Great Health Fund No. 1 focuses on investing in Taiwan’s life science and health industries. The members of the management team are all senior experts with extensive experience in life sciences, capital markets, investment, mergers and acquisitions, and post-investment management, as well as profound capabilities in business operations.
CIDC Consultants
Li-teh Hsu, the chairman of China Investment & Development (CIDC), brought together funding, professional expertise, and human resources from large companies in both Taiwan and Canada to implement investment plans benefiting both investors and the broader economy in Taiwan. He established China Investment & Development Company, Limited with a capital of NT$1.6 billion and a mission encompassing production, trade, services, and investment in technology businesses.
Over the past 14 years, CIDC Consultants has invested in 220 domestic and foreign companies, deploying more than NT$10 billion in investments through its three investment vehicles. Members of its investment team have served on the board of directors or board of supervisors of 65 companies.
Currently, CIDC Consultants manages three investment funds, with assets under its management totaling NT$6.3 billion.
In the past six years, CIDC Consultants has generated capital gains that have exceeded NT$4 billion, an outstanding record in capital management.
![Photo of CIDC Consultants]()
CIDC Consultants
Li-teh Hsu, the chairman of China Investment & Development (CIDC), brought together funding, professional expertise, and human resources from large companies in both Taiwan and Canada to implement investment plans benefiting both investors and the broader economy in Taiwan. He established China Investment & Development Company, Limited with a capital of NT$1.6 billion and a mission encompassing production, trade, services, and investment in technology businesses.
Over the past 14 years, CIDC Consultants has invested in 220 domestic and foreign companies, deploying more than NT$10 billion in investments through its three investment vehicles. Members of its investment team have served on the board of directors or board of supervisors of 65 companies.
Currently, CIDC Consultants manages three investment funds, with assets under its management totaling NT$6.3 billion.
In the past six years, CIDC Consultants has generated capital gains that have exceeded NT$4 billion, an outstanding record in capital management.
Audrey Tseng, MBA
Audrey is an advisory member of the Bio Taiwan Committee (BTC), Vice Chairperson of the Taiwan Bio Industry organization, and an Adjunct Professor at National Yang Ming Chiao Tung University.
Audrey recently retired from serving as the Deputy Chairman of PwC Taiwan, Assurance Leader, and Bio-Industry Development Committee Leader. She has over 35 years of experience in accounting and sophisticated expertise in assisting biotech industry development and business strategies.
Audrey holds an MBA from the Executive MBA Program of Fudan University and National Taiwan University, and a Master of Commerce from the Department of Accounting at National Chengchi University.
![Photo of Audrey Tseng, MBA]()
Audrey Tseng, MBA
Audrey is an advisory member of the Bio Taiwan Committee (BTC), Vice Chairperson of the Taiwan Bio Industry organization, and an Adjunct Professor at National Yang Ming Chiao Tung University.
Audrey recently retired from serving as the Deputy Chairman of PwC Taiwan, Assurance Leader, and Bio-Industry Development Committee Leader. She has over 35 years of experience in accounting and sophisticated expertise in assisting biotech industry development and business strategies.
Audrey holds an MBA from the Executive MBA Program of Fudan University and National Taiwan University, and a Master of Commerce from the Department of Accounting at National Chengchi University.
Andrew Lin, MBA
Chairman of the Board
Andrew Lin is the Chairman of TaiRx, Inc. and Nuwa Healthcare. He also serves on the Independent Board of Directors for Fubon Insurance, and is the co-founder of Affinity Capitals.
Before joining TaiRx, Andrew was Chairman of Lotus Pharmaceutical, the largest generic drug company listed on the Taiwan Stock Exchange, having previously been CEO of Hasumi Biotechnology International, a global leader in cancer vaccines and immunotherapy.
Prior to his biotech career, Andrew’s most recent positions were Chief Strategy Officer for Chicony Electronics/Clevo Group, Managing Director with Macquarie Capital, and Chief Financial Officer for Lite-On Technology Group, a US$10 billion technology giant, headquartered in Taiwan.
Andrew has also previously served as Chief Investment Officer for ABN AMRO Asset Management Taiwan, managing their US$4 billion investment portfolio, and Head of Asia Pacific Technology Research for JP Morgan Securities.
Additional experience includes management consultancy at McKinsey & Company and Booz Allen Hamilton, as well as R&D roles at AT&T Bell Laboratories, Prime Computer, and Digital Equipment Corporation.
Andrew received his MBA degree from The University of Chicago, Graduate School of Business after graduating with an MS degree in electrical and computer engineering from the University of Massachusetts at Amherst.
Andrew Lin, MBA
Chairman of the Board
Andrew Lin is the Chairman of TaiRx, Inc. and Nuwa Healthcare. He also serves on the Independent Board of Directors for Fubon Insurance, and is the co-founder of Affinity Capitals.
Before joining TaiRx, Andrew was Chairman of Lotus Pharmaceutical, the largest generic drug company listed on the Taiwan Stock Exchange, having previously been CEO of Hasumi Biotechnology International, a global leader in cancer vaccines and immunotherapy.
Prior to his biotech career, Andrew’s most recent positions were Chief Strategy Officer for Chicony Electronics/Clevo Group, Managing Director with Macquarie Capital, and Chief Financial Officer for Lite-On Technology Group, a US$10 billion technology giant, headquartered in Taiwan.
Andrew has also previously served as Chief Investment Officer for ABN AMRO Asset Management Taiwan, managing their US$4 billion investment portfolio, and Head of Asia Pacific Technology Research for JP Morgan Securities.
Additional experience includes management consultancy at McKinsey & Company and Booz Allen Hamilton, as well as R&D roles at AT&T Bell Laboratories, Prime Computer, and Digital Equipment Corporation.
Andrew received his MBA degree from The University of Chicago, Graduate School of Business after graduating with an MS degree in electrical and computer engineering from the University of Massachusetts at Amherst.
Zeng Huijin (Audrey)
Director
Audrey has worked in the accounting field for 35 years. She was the certified public accountant of many public companies such as Delta Electronics, Asus, WPG Holdings, etc. She is experienced in the capital market, international financing, tax planning, M&A, corporate governance, industrial development, and managerial strategy. Audrey has supported the IPO of countless biotech companies.
Zeng Huijin (Audrey)
Director
Audrey has worked in the accounting field for 35 years. She was the certified public accountant of many public companies such as Delta Electronics, Asus, WPG Holdings, etc. She is experienced in the capital market, international financing, tax planning, M&A, corporate governance, industrial development, and managerial strategy. Audrey has supported the IPO of countless biotech companies.
Hu, Dexing (Philip)
Director
Mr. Hu Dexing is known as the “Investment Talent” in Taiwan’s financial industry; he was the managing director of JP Morgan Asset Management and was responsible for banking and securities industry research, funds, insurance and other financial management products, management, and marketing in Fubon Group. He has rich experience in wealth management, asset management, entrepreneurial mentor and various investments, and has achieved success in product innovation, organizational change and leadership.
Hu, Dexing (Philip)
Director
Mr. Hu Dexing is known as the “Investment Talent” in Taiwan’s financial industry; he was the managing director of JP Morgan Asset Management and was responsible for banking and securities industry research, funds, insurance and other financial management products, management, and marketing in Fubon Group. He has rich experience in wealth management, asset management, entrepreneurial mentor and various investments, and has achieved success in product innovation, organizational change and leadership.
Top Taiwan Venture
Directors
Top Taiwan Venture is the largest leading venture capital management team in Taiwan. It has invested in Dr. Jang and Dr. Lee to start a business since BRIM’s A-round fundraising, supported the Company’s development along the way, and given the team capital market advice. The main investors of the venture capital funds managed by Top Taiwan Venture include 14 large insurance companies and 11 large comprehensive securities companies in Taiwan, ranking first in Taiwan.
![Photo of Top Taiwan Venture]()
Top Taiwan Venture
Directors
Top Taiwan Venture is the largest leading venture capital management team in Taiwan. It has invested in Dr. Jang and Dr. Lee to start a business since BRIM’s A-round fundraising, supported the Company’s development along the way, and given the team capital market advice. The main investors of the venture capital funds managed by Top Taiwan Venture include 14 large insurance companies and 11 large comprehensive securities companies in Taiwan, ranking first in Taiwan.
Haishan Jang, PhD
Vice Chairman, CGS (Chief Global Strategist) of BRIM
Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research through to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation.
Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone.
Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.
Haishan Jang, PhD
Vice Chairman, CGS (Chief Global Strategist) of BRIM
Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research through to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation.
Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone.
Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.
Isaiah Capital LLC
Isaiah Capital specializes in the investment and management of innovative technology industries. One of its representatives was the director of BRIM′s A round of fundraising and also invested in BRIM′s B and C rounds of fundraising. In the D round of fundraising, Isaiah Capital coordinated with BRIM to bring investors with more international capital market experience to help BRIM execute IPO strategies and establish international financial planning. Isaiah Capital also joined the most recent Series E round to continue to support BRIM′s growth.
Isaiah Capital LLC
Isaiah Capital specializes in the investment and management of innovative technology industries. One of its representatives was the director of BRIM′s A round of fundraising and also invested in BRIM′s B and C rounds of fundraising. In the D round of fundraising, Isaiah Capital coordinated with BRIM to bring investors with more international capital market experience to help BRIM execute IPO strategies and establish international financial planning. Isaiah Capital also joined the most recent Series E round to continue to support BRIM′s growth.
Haishan Jang
Chairwoman and Chief Executive Officer
Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nullam imperdiet diam nibh, eget faucibus risus imperdiet sit amet. Praesent ut tortor efficitur, auctor urna non, interdum ipsum. Fusce pellentesque tincidunt nunc, vitae tincidunt diam vestibulum nec. Vivamus sagittis, est ac tempor pharetra, est lorem sollicitudin dui, congue fermentum diam augue volutpat nulla. Duis fringilla accumsan augue, nec tincidunt nisl. Proin sed sem nec leo porta ultricies at consequat quam. Phasellus sit amet ipsum magna. Donec facilisis massa vitae leo varius semper. Interdum et malesuada fames ac ante ipsum primis in faucibus.
Haishan Jang
Chairwoman and Chief Executive Officer
Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Nullam imperdiet diam nibh, eget faucibus risus imperdiet sit amet. Praesent ut tortor efficitur, auctor urna non, interdum ipsum. Fusce pellentesque tincidunt nunc, vitae tincidunt diam vestibulum nec. Vivamus sagittis, est ac tempor pharetra, est lorem sollicitudin dui, congue fermentum diam augue volutpat nulla. Duis fringilla accumsan augue, nec tincidunt nisl. Proin sed sem nec leo porta ultricies at consequat quam. Phasellus sit amet ipsum magna. Donec facilisis massa vitae leo varius semper. Interdum et malesuada fames ac ante ipsum primis in faucibus.
Leadership Team
Amanda Yen
VP of Finance
Amanda Yen graduated from Chung Yuan Christian University and has over 25 years′ experience in accounting and corporate tax. Before BRIM, she was the Financial Controller of GroupM Limited Taiwan Branch leading 20 direct reports in the accounting department to accomplish all financing and accounting-related reports and tax affairs. Prior to that, she was the Finance and Accounting Director of Lotus Pharmaceutical Co. Ltd. (Alvogen Group), managing financial affairs for a listed Taiwan company and its five global subsidiaries. Previous positions include Accounting Director for TaiGen Biotechnology and Accounting Manager at TNT Express Taiwan Branch.
Amanda Yen
VP of Finance
Amanda Yen graduated from Chung Yuan Christian University and has over 25 years′ experience in accounting and corporate tax. Before BRIM, she was the Financial Controller of GroupM Limited Taiwan Branch leading 20 direct reports in the accounting department to accomplish all financing and accounting-related reports and tax affairs. Prior to that, she was the Finance and Accounting Director of Lotus Pharmaceutical Co. Ltd. (Alvogen Group), managing financial affairs for a listed Taiwan company and its five global subsidiaries. Previous positions include Accounting Director for TaiGen Biotechnology and Accounting Manager at TNT Express Taiwan Branch.
Yi-Chun Maria Chen, PhD
VP of Business Development
Dr Yi-Chun Maria Chen is a cellular immunologist, specializing in the study of T-cell and B-cell activities. She received her PhD in Biochemistry at Stony Brook University and did post-doctoral research at UCSF and Genentech. Maria returned to Taiwan in 2015 and joined Immunwork, Inc. to help set up their business and fundraising strategies. Since joining BRIM in 2020, she has devoted herself to the development of new drugs and the business development of startup companies.
Yi-Chun Maria Chen, PhD
VP of Business Development
Dr Yi-Chun Maria Chen is a cellular immunologist, specializing in the study of T-cell and B-cell activities. She received her PhD in Biochemistry at Stony Brook University and did post-doctoral research at UCSF and Genentech. Maria returned to Taiwan in 2015 and joined Immunwork, Inc. to help set up their business and fundraising strategies. Since joining BRIM in 2020, she has devoted herself to the development of new drugs and the business development of startup companies.
Su Lin, MS
VP of Operation Development
Su Lin gained her Master of Science in Hospital Pharmacy Administration at Temple University, Graduate School of Pharmacy. She has nearly 20 years’ experience in the pharmaceutical industry, specifically in regulatory affairs and labeling, and has worked in global pharma such as Intercept and Regeneron Pharmaceuticals.
Su Lin, MS
VP of Operation Development
Su Lin gained her Master of Science in Hospital Pharmacy Administration at Temple University, Graduate School of Pharmacy. She has nearly 20 years’ experience in the pharmaceutical industry, specifically in regulatory affairs and labeling, and has worked in global pharma such as Intercept and Regeneron Pharmaceuticals.
Erin Chang, MS
VP of Portfolio Development
Erin Chang graduated from the Graduate Institute of Toxicology at the National Taiwan University and has more than 15 years’ of experience in new drug development and project management. She previously worked at TTY Biopharm and Taiwan Liposome Company, where she participated in the discovery and clinical development of biologics, peptides, and special dosage new drugs.
Erin Chang, MS
VP of Portfolio Development
Erin Chang graduated from the Graduate Institute of Toxicology at the National Taiwan University and has more than 15 years’ of experience in new drug development and project management. She previously worked at TTY Biopharm and Taiwan Liposome Company, where she participated in the discovery and clinical development of biologics, peptides, and special dosage new drugs.
Mei-Hui Kuo
COO
Mei-Hui Kuo has over 30 years’ experience in the biotechnology pharmaceutical industry. Her most recent role was COO at Senhwa Biosciences, with previous senior positions including VP of Operations at the Development Center for Biotechnology, Director of New Product Development at TTY Biopharm, Senior VP and Board Member at CDIB Bioscience Venture Management, and Assistant VP in the Life Science Investment Unit of Overseas Business Department at China Development Industrial Bank. Mei-Hui has extensive experience in the operation and management of biotechnology companies and is also very familiar with the domestic and foreign investment environment.
Mei-Hui received her MS degree in Plant Pathology and Microbiology from National Taiwan University.
Mei-Hui Kuo
COO
Mei-Hui Kuo has over 30 years’ experience in the biotechnology pharmaceutical industry. Her most recent role was COO at Senhwa Biosciences, with previous senior positions including VP of Operations at the Development Center for Biotechnology, Director of New Product Development at TTY Biopharm, Senior VP and Board Member at CDIB Bioscience Venture Management, and Assistant VP in the Life Science Investment Unit of Overseas Business Department at China Development Industrial Bank. Mei-Hui has extensive experience in the operation and management of biotechnology companies and is also very familiar with the domestic and foreign investment environment.
Mei-Hui received her MS degree in Plant Pathology and Microbiology from National Taiwan University.
Wen Chyi Shyu, PhD
CEO
With more than two decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and commercial expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in R&D ranges from pre-clinical and clinical drug metabolism to pharmacokinetic drug discovery, drug development, and life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab.
Wen Chyi brings to BRIM extensive industry experience and a passion for driving drug discovery and development innovation. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee of the New England Drug Metabolism Discussion Working Group (NEDMDG) to identify and improve the drug discovery process and to shorten study turnaround time. Wen Chyi has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development.
She has a passion for training, motivating, and developing research scientists to become successful pharmaceutical executives and has built numerous international and multi-disciplinary teams.
Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.
Wen Chyi Shyu, PhD
CEO
With more than two decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and commercial expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in R&D ranges from pre-clinical and clinical drug metabolism to pharmacokinetic drug discovery, drug development, and life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab.
Wen Chyi brings to BRIM extensive industry experience and a passion for driving drug discovery and development innovation. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee of the New England Drug Metabolism Discussion Working Group (NEDMDG) to identify and improve the drug discovery process and to shorten study turnaround time. Wen Chyi has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development.
She has a passion for training, motivating, and developing research scientists to become successful pharmaceutical executives and has built numerous international and multi-disciplinary teams.
Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.
Haishan Jang, PhD
Vice Chairman, CGS (Chief Global Strategist) of BRIM
Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research through to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation.
Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone.
Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.
Haishan Jang, PhD
Vice Chairman, CGS (Chief Global Strategist) of BRIM
Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research through to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation.
Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone.
Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.
Frank W. Lee
CSO
Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn®, Anaprox®, and Ticlid®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy.
In addition to holding a Board position at BRIM, Frank sits on the board at Foresee Pharmaceuticals in Taiwan. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs.
Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.
Frank W. Lee
CSO
Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn®, Anaprox®, and Ticlid®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy.
In addition to holding a Board position at BRIM, Frank sits on the board at Foresee Pharmaceuticals in Taiwan. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs.
Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.
Senior Scientific Team
Wayne Liaw
Sr. Formulation Fellow
Wayne Liaw
Sr. Formulation Fellow
Chyau Liang
Sr. IP Fellow
Chyau Liang
Sr. IP Fellow
Conrad Tou
Sr. Biostatistic Fellow
Conrad Tou
Sr. Biostatistic Fellow
Carl Alden
Sr. Toxicology Fellow
Carl Alden
Sr. Toxicology Fellow